These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24950403)

  • 1. Role of genomics in translational research for Parkinson's disease.
    Sekiyama K; Takamatsu Y; Waragai M; Hashimoto M
    Biochem Biophys Res Commun; 2014 Sep; 452(2):226-35. PubMed ID: 24950403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease.
    Singh MP; Patel S; Dikshit M; Gupta YK
    Indian J Biochem Biophys; 2006 Apr; 43(2):69-81. PubMed ID: 16955754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of Parkinson's disease genetics.
    Lorincz MT
    Semin Neurol; 2006 Nov; 26(5):492-8. PubMed ID: 17048150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heredity in Parkinson's disease: new findings.
    Lev N; Melamed E
    Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress and genetics in the pathogenesis of Parkinson's disease.
    Zhang Y; Dawson VL; Dawson TM
    Neurobiol Dis; 2000 Aug; 7(4):240-50. PubMed ID: 10964596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlapping molecular signatures in Parkinson's patients' leukocytes before and after treatment and in mouse model brain regions.
    Soreq L; Bergman H; Israel Z; Soreq H
    CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1086-93. PubMed ID: 24040822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convergence of miRNA expression profiling, α-synuclein interacton and GWAS in Parkinson's disease.
    Martins M; Rosa A; Guedes LC; Fonseca BV; Gotovac K; Violante S; Mestre T; Coelho M; Rosa MM; Martin ER; Vance JM; Outeiro TF; Wang L; Borovecki F; Ferreira JJ; Oliveira SA
    PLoS One; 2011; 6(10):e25443. PubMed ID: 22003392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs in Parkinson's disease.
    Mouradian MM
    Neurobiol Dis; 2012 May; 46(2):279-84. PubMed ID: 22245218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies for Parkinson's disease based on data derived from genetic research.
    Riess O; Berg D; Krüger R; Schulz JB
    J Neurol; 2003 Feb; 250 Suppl 1():I3-10. PubMed ID: 12761628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O
    Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease.
    Dumitriu A; Golji J; Labadorf AT; Gao B; Beach TG; Myers RH; Longo KA; Latourelle JC
    BMC Med Genomics; 2016 Jan; 9():5. PubMed ID: 26793951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era.
    Verstraeten A; Theuns J; Van Broeckhoven C
    Trends Genet; 2015 Mar; 31(3):140-9. PubMed ID: 25703649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease and Parkinson's disease genome-wide association study top hits and risk of Parkinson's disease in Korean population.
    Chung SJ; Jung Y; Hong M; Kim MJ; You S; Kim YJ; Kim J; Song K
    Neurobiol Aging; 2013 Nov; 34(11):2695.e1-7. PubMed ID: 23820587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genetic background of Parkinson's disease: current progress and future prospects.
    Kalinderi K; Bostantjopoulou S; Fidani L
    Acta Neurol Scand; 2016 Nov; 134(5):314-326. PubMed ID: 26869347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease: 10 years of progress, 1997-2007.
    Fahn S
    Mov Disord; 2010; 25 Suppl 1():S2-14. PubMed ID: 20187239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. alpha-Synuclein promoter confers susceptibility to Parkinson's disease.
    Pals P; Lincoln S; Manning J; Heckman M; Skipper L; Hulihan M; Van den Broeck M; De Pooter T; Cras P; Crook J; Van Broeckhoven C; Farrer MJ
    Ann Neurol; 2004 Oct; 56(4):591-5. PubMed ID: 15455394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synucleins: are they two-edged swords?
    Surguchov A
    J Neurosci Res; 2013 Feb; 91(2):161-6. PubMed ID: 23150342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a risk haplotype of the alpha-synuclein gene in Japanese with sporadic Parkinson's disease.
    Kobayashi H; Ujike H; Hasegawa J; Yamamoto M; Kanzaki A; Sora I
    Mov Disord; 2006 Dec; 21(12):2157-64. PubMed ID: 17078049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.